TGF beta1 isoform specific antisense oligonucleotide - Isarna Therapeutics
Alternative Names: TGF B1 isoform specific antisense oligonucleotide - Isarna TherapeuticsLatest Information Update: 23 Aug 2023
At a glance
- Originator Isarna Therapeutics
- Class Antifibrotics; Antineoplastics; Antisense oligonucleotides; Hepatoprotectants
- Mechanism of Action RNA interference; Transforming growth factor beta1 expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Fibrosis; Non-alcoholic steatohepatitis
- Research Cancer
Most Recent Events
- 29 Jul 2023 Early research in Cancer in Germany (Parenteral) (Isarna Therapeutics pipeline; July 2023)
- 29 Jul 2023 Preclinical trials in Fibrosis in Germany (Parenteral) (Isarna Therapeutics pipeline; July 2023)
- 29 Jul 2023 Preclinical trials in Non-alcoholic steatohepatitis in Germany (Parenteral) (Isarna Therapeutics pipeline; July 2023)